Cosmo Pharmaceuticals Statistics
Total Valuation
ETR:C43 has a market cap or net worth of EUR 961.59 million. The enterprise value is 829.86 million.
Market Cap | 961.59M |
Enterprise Value | 829.86M |
Important Dates
The last earnings date was Thursday, March 6, 2025.
Earnings Date | Mar 6, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Current Share Class | n/a |
Shares Outstanding | n/a |
Shares Change (YoY) | +1.94% |
Shares Change (QoQ) | +3.31% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 8.52M |
Valuation Ratios
The trailing PE ratio is 7.22.
PE Ratio | 7.22 |
Forward PE | n/a |
PS Ratio | n/a |
PB Ratio | n/a |
P/TBV Ratio | 3.08 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.24, with an EV/FCF ratio of 5.26.
EV / Earnings | 6.23 |
EV / Sales | 3.16 |
EV / EBITDA | 5.24 |
EV / EBIT | 5.67 |
EV / FCF | 5.26 |
Financial Position
The company has a current ratio of 4.19, with a Debt / Equity ratio of 0.00.
Current Ratio | 4.19 |
Quick Ratio | 3.39 |
Debt / Equity | 0.00 |
Debt / EBITDA | 0.01 |
Debt / FCF | 0.01 |
Interest Coverage | 2,809.09 |
Financial Efficiency
Return on equity (ROE) is 29.31% and return on invested capital (ROIC) is 20.39%.
Return on Equity (ROE) | 29.31% |
Return on Assets (ROA) | 15.87% |
Return on Invested Capital (ROIC) | 20.39% |
Return on Capital Employed (ROCE) | 24.88% |
Revenue Per Employee | 828,534 |
Profits Per Employee | 413,776 |
Employee Count | 322 |
Asset Turnover | 0.45 |
Inventory Turnover | 3.27 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -18.88% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -18.88% |
50-Day Moving Average | 64.75 |
200-Day Moving Average | 71.05 |
Relative Strength Index (RSI) | 45.79 |
Average Volume (20 Days) | 41 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ETR:C43 had revenue of EUR 266.79 million and earned 133.24 million in profits. Earnings per share was 8.12.
Revenue | 266.79M |
Gross Profit | 221.43M |
Operating Income | 148.88M |
Pretax Income | 153.37M |
Net Income | 133.24M |
EBITDA | 160.47M |
EBIT | 148.88M |
Earnings Per Share (EPS) | 8.12 |
Balance Sheet
The company has 142.96 million in cash and 2.20 million in debt, giving a net cash position of 140.76 million.
Cash & Cash Equivalents | 142.96M |
Total Debt | 2.20M |
Net Cash | 140.76M |
Net Cash Per Share | n/a |
Equity (Book Value) | 505.09M |
Book Value Per Share | 31.12 |
Working Capital | 153.99M |
Cash Flow
In the last 12 months, operating cash flow was 162.41 million and capital expenditures -4.55 million, giving a free cash flow of 157.86 million.
Operating Cash Flow | 162.41M |
Capital Expenditures | -4.55M |
Free Cash Flow | 157.86M |
FCF Per Share | n/a |
Margins
Gross margin is 83.00%, with operating and profit margins of 55.81% and 49.94%.
Gross Margin | 83.00% |
Operating Margin | 55.81% |
Pretax Margin | 57.49% |
Profit Margin | 49.94% |
EBITDA Margin | 60.15% |
EBIT Margin | 55.81% |
FCF Margin | 59.17% |
Dividends & Yields
This stock pays an annual dividend of 2.00, which amounts to a dividend yield of 3.45%.
Dividend Per Share | 2.00 |
Dividend Yield | 3.45% |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | 2 |
Payout Ratio | 24.09% |
Buyback Yield | -1.94% |
Shareholder Yield | 1.51% |
Earnings Yield | 13.86% |
FCF Yield | 16.42% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
ETR:C43 has an Altman Z-Score of 7.21.
Altman Z-Score | 7.21 |
Piotroski F-Score | n/a |